Clinical evaluation of the QMS® Tacrolimus Immunoassay

• The QMS tacrolimus immunoassay showed good overall analytical performance.
• Comparison studies showed the overall proportional bias of 1.17.
• Comparisons of liver and kidney transplant patients showed significant slope biases.
• Comparison of other remaining transplant patients showed no slope bias.
• Overall bias is due to more liver and kidney transplant patients in the study.

BackgroundTacrolimus, a widely used immunosuppressant, inhibits T-lymphocyte signal transduction and cytokine upregulation. We evaluated and compared the performance of a newly developed tacrolimus immunoassay method to LC–MS/MS.MethodAnalytical performance was assessed using quality control materials and whole blood patient samples. Interferences studies were performed using pooled whole-blood samples spiked with each interferent, respectively. Comparison studies were conducted using 145 de-identified whole blood samples collected after routine tacrolimus analysis by LC–MS/MS.ResultsCVs were between 3.9 and 8.1% and the method was linear (r2 = 0.99) up to 30.0 ng/ml. Calibration was stable ≤ 12 days and LOQ was 0.7 ng/ml (14.4% CV). Bilirubin (≤ 48 mg/dl), hemoglobin (≤ 345 mg/dl), and triglycerides (< 2800 mg/dl) showed no significant interference. Comparison (Passing–Bablok regression) for all samples showed a proportional bias of 17%. Comparisons of liver and kidney transplant patients showed slope biases of 22% and 31%, respectively, whereas other remaining transplant patients (stem cell, heart, lung, and islet) showed a slope bias of 0.98.ConclusionsOverall, the QMS Tacrolimus Immunoassay showed good analytical performance. Comparison studies showed a proportional bias of 17%, which can be attributed to the significant number of liver and kidney transplant patients present in this study (121/145).